Namrata Saroj
Known title: Chief Business OfficerCIK: 0002073624
Associated companies
Transaction History
| OCUL | ▲ Buy | Grant | 79,112 | $0 | 1/2/2026 | View on chart |
| OCUL | ▼ Sell | Open Market | 25,865 | $278K | 11/5/2025 | View on chart |
| OCUL | ▲ Buy | Grant | 79,112 | $0 | 1/2/2026 | View on chart |
| OCUL | ▼ Sell | Open Market | 25,865 | $278K | 11/5/2025 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
OCUL: UBS initiates coverage and Nasdaq grant filing reported
UBS has started coverage of Ocular Therapeutix and set a price target of $14. The company also disclosed inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). OCUL presented its latest data at the Euretina 2026 conference, highlighting ongoing development efforts. Analyst commentary this week varies, with some listing the stock among top healthcare picks while others note its unprofitable status.
OCUL: UBS initiates coverage and Nasdaq grant filing reported. UBS has started coverage of Ocular Therapeutix and set a price target of $14. The company also disclosed inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). OCUL presented its latest data at the Euretina 2026 conference, highlighting ongoing development efforts. Analyst commentary this week varies, with some listing the stock among top healthcare picks while others note its unprofitable status.